Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M44,885Revenue $M2,234Net Margin (%)26.0Altman Z-Score32.4
Enterprise Value $M43,120EPS $3.3Operating Margin %33.7Piotroski F-Score6
P/E(ttm)67.9Beneish M-Score-2.5Pre-tax Margin (%)33.8Higher ROA y-yY
Price/Book11.210-y EBITDA Growth Rate %--Quick Ratio4.6Cash flow > EarningsY
Price/Sales17.75-y EBITDA Growth Rate %52.3Current Ratio4.9Lower Leverage y-yN
Price/Free Cash Flow77.1y-y EBITDA Growth Rate %23.9ROA % (ttm)15.2Higher Current Ratio y-yN
Dividend Yield %--PEG1.3ROE % (ttm)19.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M200ROIC % (ttm)39.2Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJoel Greenblatt 2015-03-31 Reduce-0.09%$171.42 - $189.07
($181.01)
$ 198.7610%Reduce 72.94%23,261
ALXNRon Baron 2015-03-31 Add0.02%$171.42 - $189.07
($181.01)
$ 198.7610%Add 124.13%41,163
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 198.767%Add 4665.74%85,974
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 198.767%Add 41.92%18,366
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 198.7621%Reduce 89.45%1,804
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 198.7621%Add 27.56%12,941
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 198.7626%Add 240.11%17,094
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 198.7626%New holding5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 198.7626%New holding10,218
ALXNJoel Greenblatt 2013-03-31 Sold Out -0.07%$83.39 - $102.57
($93.13)
$ 198.76113%Sold Out0
ALXNJoel Greenblatt 2012-12-31 Buy 0.07%$87.97 - $118.15
($98.27)
$ 198.76102%New holding12,977
ALXNGeorge Soros 2012-06-30 Sold Out -0.07%$83.74 - $98.82
($91.04)
$ 198.76118%Sold Out0
ALXNGeorge Soros 2012-03-31 Buy 0.07%$70.29 - $94.31
($75.85)
$ 198.76162%New holding50,000
ALXNJoel Greenblatt 2011-09-30 Sold Out -0.0882%$47.81 - $66.99
($56.19)
$ 198.76254%Sold Out0
ALXNJoel Greenblatt 2011-06-30 Buy 0.09%$44.61 - $52.195
($47.91)
$ 198.76315%New holding13,417
ALXNGeorge Soros 2011-06-30 Sold Out $44.61 - $52.195
($47.91)
$ 198.76315%Sold Out0
ALXNGeorge Soros 2011-03-31 Add$40.665 - $49.865
($45.18)
$ 198.76340%Add 90.48%8,000
ALXNGeorge Soros 2010-12-31 Reduce$31.78 - $41.17
($36.7)
$ 198.76442%Reduce 87.61%8,400
ALXNGeorge Soros 2010-09-30 Buy 0.03%$24.82 - $32.49
($28.22)
$ 198.76604%New holding67,800
ALXNGeorge Soros 2010-06-30 Sold Out -0.17%$24.31 - $28.34
($26.53)
$ 198.76649%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELL LEONARDDirector 2015-06-18Sell27,835$179.6310.65view
Moriarty John BEVP & General Counsel 2015-06-11Sell914$17016.92view
Monnet DominiqueSVP, Chief Marketing Officer 2015-05-20Sell256$162.422.39view
MACKAY MARTINEVP & Global Head of R&D 2015-05-14Sell4,056$160.3323.97view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-04-27Sell6,032$181.579.47view
BELL LEONARDCEO 2015-03-19Sell15,952$188.075.68view
O'Neill JulieEVP. Global Operations 2015-03-02Sell11,665$101.4995.84view
Sinha VikasEVP & CFO 2015-03-02Sell487$180.3410.21view
MACKAY MARTINEVP & Global Head of R&D 2015-03-02Sell370$180.3410.21view
Moriarty John BEVP & General Counsel 2015-03-02Sell280$180.3410.21view

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 

More From Other Websites
Will Rising Costs Hurt Alexion (ALXN) Earnings in Q2? - Analyst Blog Jul 28 2015
Is Gilead Sciences About to Make an Acquisition? Jul 27 2015
JP Morgan Moves Alexion Pharma To Overweight, Says Strensiq And Kanuma Are $1.7B Opportunity Jul 27 2015
What to Expect from Biogen and Celgene Jul 20 2015
4 Large Cap Biotech Stocks to Buy Before Earnings Jul 20 2015
Alexion, Incyte Stage Breakouts Jul 14 2015
Big Cap 20: Biotech Red-Hot As Medicals Stay Dominant Jul 13 2015
Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015 Jul 13 2015
Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015 Jul 13 2015
Short Sellers Shy Away From Biotech Stocks Jul 13 2015
5 Trade Ideas for Monday: American Eagle, Alexion, Atmel, Federated & Lending Tree Jul 12 2015
Halftime's hottest trades: LNKD, CUDA, ALXN & QCOM Jul 10 2015
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
The Zacks Analyst Blog Highlights: Vertex, Biogen, Applied Genetic, Gilead and Alexion - Press... Jul 09 2015
Alexion Hypophosphatasia Drug Strensiq Approved in Japan - Analyst Blog Jul 07 2015
Singapore's giant wealth fund still bullish on China Jul 07 2015
Big Cap 20: Does Edwards Lifesciences Have More Left? Jul 06 2015
Strensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with... Jul 06 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK